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A 57-year-old man was referred to the Hypertension Clinic of the
University Department of Medicine at the Sotiria General Hospital
because of uncontrolled hypertension and renal insufficiency. He was a
nonsmoker and drank alcohol only socially. He reported being overweight
since adulthood. His father had had hypertension and died of a myocardial
infarction at age 67. The patient had been known to be hypertensive since
the age of 28. At that time, his blood pressure was approximately 150/100
mm Hg, and a number of investigations, including blood chemistry,
urinalysis, and intravenous urography, revealed no primary cause of the
hypertension. He was instructed to reduce his salt and caloric intake, but
he did not cooperate.
At age 35, his blood pressure was 160/110mm Hg and serum creatinine
1.1 mg/dl. Antihypertensive treatment with a thiazide diuretic and a
a-blocker was prescribed, but after a few weeks, when his blood pressure
had declined to 130/90 mm Hg, the patient complained of tiredness and
sexual dysfunction, and he decided to abandon the regimen. At age 49,
routine examination disclosed a blood pressure of 170/105 mm Hg; serum
creatinine, 1.5 mg/dl; and creatinine clearance, 65.3 ml/min. Urinalysis
revealed trace proteinuria with no abnormalities in the urinary sediment.
An electrocardiogram was normal. Ultrasonography revealed decreased
size of both kidneys with no parenchymal abnormality. Administration of
enalapril, 10 mg daily, satisfactorily controlled his blood pressure (120/85
mm Hg) within a few weeks. However, the patient decreased his daily dose
to 5 mg because he "didn't feel well when [his] blood pressure was low."
One year later, his blood pressure was 160/98 mm Hg and the serum
creatinine 1.6 mg/dl. The next year, his serum creatinine had risen to 2.2
mg/dl and it remained virtually unchanged (2.1 mg/dl) after one more
year. At that time, the patient discontinued treatment. Over the ensuing
three years, occasional blood pressure measurements revealed pressures
ranging between 150/95 mm Hg and 180/1 10 mm Hg.
Two years before referral, he was admitted to another hospital for
removal of an adenomatous colonic polyp. Routine hematologic and
biochemical investigation at that time revealed: hematocrit, 40.9%; blood
glucose, 97 mgldl; blood urea, 130 mg/dl; serum creatinine, 4.8 mg/dl;
serum uric acid, 11.2 mg/dl; serum cholesterol, 165 mg/dl; triglycerides,
390 mg/dl; HDL cholesterol, 26 mg/dl; total serum protein, 5.1 gldl; serum
sodium, 145 mEq/liter; potassium, 3.9 mEq/liter; total calcium, 9.0 mg/dl;
and phosphate, 4.0 mg/dl. On discharge, the patient was instructed to take
lisinopril, 10 mg daily, and allopurinol, 200 mg daily.
On presentation at the outpatient clinic, his blood pressure while sitting
was 160/98 mm Hg, and the pulse rate was 80 beats/mm and regular. Body
mass index was 30 kg/m2. Thoracic and cardiac examinations were normal,
and no peripheral edema was noted. The abdomen was not remarkable;
no abdominal bruit was audible. Funduscopy revealed generalized nar-
rowing of the retinal arteries (grade-I hypertensive retinopathy, Keith-
Wagener classification). Investigations showed the following: hematocrit,
42%; blood urea, 117 mg/dl; serum creatinine, 3.7 mg/dl; uric acid, 6.5
mg/dl; sodium, 142 mEq/liter; and potassium, 4.9 mEq/liter. Urinalysis
disclosed trace protein with no abnormalities in the sediment. Electrocar-
diographic evaluation showed left-ventricular hypertrophy with voltage
criteria. Echocardiography revealed concentric left-ventricular hypertro-
phy. On abdominal ultrasound, the right kidney measured 9.5 X 4.2 cm,
the left kidney 9.3 < 4.0 cm, and the prostate 4.5 >< 5.0 X 4.0 cm. The
patient was instructed to increase the daily dose of lisinopril to 20 mg and
to follow a low-caloric, low-protein diet.
Discussion
DR. THEODORE D. MOUNTOKALAKIS (Professor of Medicine, and
Head, Third Department of Internal Medicine, University of Athens
Medical Schooi Sotiria General Hospital, Athens, Greece): This
man illustrates a problem common in everyday medical practice:
impaired renal function in patients known to be hypertensive for
several years. This clinical problem has focused attention on two
central questions: First, can essential hypertension cause progres-
sive renal disease? Second, can antihypertensive treatment pre-
vent or delay progressive deterioration of renal function? In this
review, I will examine several aspects of these questions, starting
with an outline of the structural basis of hypertensive renal
disease. I then will discuss epidemiologic observations that indi-
cate a relationship between blood pressure and progressive renal
disease. Next I will briefly consider the current hypotheses about
the mechanisms by which hypertension might cause renal injury.
Finally, I will attempt to critically evaluate the clinical evidence
suggesting that antihypertensive therapy in general, or certain
classes of antihypertensive drugs in particular, protect renal
function.
Renal damage in hypertension
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The association between hypertension and renal disease was
first suggested by Richard Bright, who in 1836 observed "that the
hypertrophy of the heart seems, in some degree, to have kept pace
with the advance of disease of the kidneys" [11. The discovery of
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landmark experiment on the production of hypertension by partial
constriction of the renal arteries, established the role of the kidney
in the genesis of hypertension [2]. Almost 20 years later, when
awareness of increased mortality in hypertension led to an analysis
of the causes of death in hypertensive patients, it became clear
that not only can the kidney cause hypertension, but hypertension
can adversely affect the kidney.
High blood pressure has long been recognized as a cause of
renal disease, particularly in patients with malignant hypertension.
In fact, uremia was the cause of death in almost one-half of the
cases of malignant hypertension before antihypertensive treat-
ment became available. "Malignant arteriolar nephrosclerosis" is
the term used to describe the marked renal vascular changes
caused by the malignant phase of hypertension. These changes
include: (1) exuberant proliferation of smooth muscle cells in the
intimal layer of interlobular and small arteries, an appearance
referred to as "onion skin"; and (2) fibrinoid necrosis of smooth
muscle cells of small arteries and arterioles which, when involving
the afferent arteriole, can extend into the glomerulus and lead to
focal glomerular destruction [3].
In contradistinction to malignant arteriolar nephrosclerosis,
"benign arteriolar nephrosclerosis" refers to renal disease associ-
ated with nonmalignant hypertension. On gross pathologic exam-
ination, the kidney appears contracted, with a generalized gran-
ular surface. Morphologic abnormalities include shrinkage,
hypocellularity, and eventual sclerosis of the glomerular tuft, as
well as atrophy of tubular cells and interstitial abnormalities; these
changes are most notable in the vasculature extending from the
larger arcuate arteries out to the afferent arterioles. Typically,
there is a thickening of the vascular intima which, depending on
the size of the vessel, may be due to accumulation of hyaline or
extracellular proteinaceous material in the large arcuate arteries
or to proliferation of vascular smooth cells in the smaller inter-
lobular arteries. The internal elastic lamina both in the arcuate
and interlobular arteries exhibit reduplication. The most specific
change, however, is hyalinization of the afferent arterioles, with
degeneration of their internal elastic and basement membranes,
and fibrinoid necrosis of the entire vessel [3].
Incidence of hypertensive renal disease
Forty years ago, when no specific antihypertensive therapy was
available, Perera studied the natural course of essential hyperten-
sion by following 500 patients until death [1. This landmark
article should be studied carefully by all physicians caring for
patients with hypertension. Of the 500 patients, 7% developed
malignant hypertension. In addition, proteinuria was found in
42%, and renal insufficiency in 18% of these patients. This latter
complication was more common than either coronary heart
disease (16%) or cerebrovascular accidents (12%). Perera esti-
mated that, apart from deaths due to uremia in the course of the
malignant phase of hypertension, renal insufficiency was a con-
tributing factor in a further 10% of deaths. Increasing azotemia
was included in the list of "terminating morbid events" in the
Veterans Administration Cooperative Study of the late 1960s at a
time when hydrochiorothiazide, reserpine, and hydralazine were
the only available antihypertensive drugs [5, 61. However, the total
number of renal events was very small. On the other hand,
prospective community-based studies, such as the Framingham
Study, demonstrated that initial blood pressure is related to
congestive heart failure, cerebrovascular accidents, coronary heart
disease, and intermittent claudication, but the study provided
virtually no information on renal end points [7, 81.
In recent years, concern about the renal consequences of
hypertension has revived because of an increasing prevalence of
hypertension as a presumptive cause of end-stage renal disease in
national registries both in the United States and in Europe. Such
an increase contrasts sharply with the striking decline in mortality
rates from both stroke and coronary heart disease in most
economically developed countries. According to the United States
Renal Data System, between 1983 and 1987 the incidence of
hypertension-related end-stage renal disease rose by 8.3% per
year, while the total incidence of end-stage renal failure increased
by 5.7% [9]. In Europe, at the end of 1992, "renal vascular
disease" ("unspecified" or assumed to be due to hypertension)
was the primary renal disease in 14% of all new patients beginning
renal replacement treatment and in 21.5% of new patients over 65
years old [101. Nevertheless, marked geographic and racial varia-
tions exist. In 1989, "renal vascular disease" was recorded in only
7% of patients beginning renal replacement therapy in Germany
and in 14% in France and Italy [111; in the same year, hyperten-
sion was regarded as the underlying cause in almost one-third of
the patients who began renal replacement therapy in the United
States, and was especially common in blacks (relative risk for
gender- and age-adjusted comparison with whites, 6.4) [12].
Of course, it is possible that the registry-based incidence of
hypertensive renal disease is overestimated, because a clinical
diagnosis of essential hypertension as a cause of end-stage renal
disease is usually made by exclusion, thus allowing for consider-
able misclassification. Other types of renal disease, such as
atherosclerotic occlusion of the renal arteries (frequent in elderly
hypertensive patients), cholesterol crystal microembolization,
chronic poststreptococcal glomerulonephritis, and interstitial ne-
phritis, can mimic hypertensive nephrosclerosis [13, 14]. In a
prospective study of 56 consecutive patients in whom hypertensive
nephrosclerosis was diagnosed on the basis of clinical criteria, the
diagnosis was proven to be wrong by histologic evaluation, duplex
ultrasonography, or renal angiography in approximately 60% of
cases [7]. An additional problem arises from the lack of specificity
of the histologic features of hypertensive nephrosclerosis. Similar
changes can be observed in the aging kidneys of normotensive
subjects in association with conditions such as glomerulonephritis
and chronic interstitial disease [13]. Finally, the increased inci-
dence of hypertensive renal disease also might reflect, at least in
part, more referrals for renal replacement therapy. Thus, because
arterial hypertension is especially common in the elderly, the new
population of older patients entering dialysis programs is likely to
produce an increase in the incidence of hypertensive renal
vascular disease. Nevertheless, because arterial hypertension is far
more common than renal failure, even a very low incidence of
hypertension-related renal impairment could account for the high
proportion of patients beginning dialysis as a consequence of
nephrosclerosis [12—14].
In addition to the registry-based statistics, the relationship
between hypertension and end-stage renal disease has been
examined in retrospective studies (Table 1). Brazy et al reviewed
the medical records of 86 patients on chronic dialysis in whom
sufficient data before dialysis were available to determine the rates
of progression of renal insufficiency by the slope of the reciprocal
of plasma creatinine versus time plot [15]. A mean diastolic blood
pressure lower than 90 mm Hg was associated with a rate of
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Table 1. Main studies of the effect of hypertension on renal function'
Study Subjects and followup Number Index_- Results
Retrospective studies
Brazy et al, 1989 [15]t Patients on dialysis 86 uSer Rate of decline greater in patients with
DBP >90 mm Hg
Rostand et al, 1989 [17] Hypertensives 181 Scr No relationship between BP and increase
in Scr within one year or more




Scr Rate of increase greater in
hypertensivcs
Prospective studies




Proteinuria in 42%, renal failure in 18%
Lindeman et al, 1984 [21] General population followed for
at least 8 years
446 Ccr Correlation between MBP and rate of
decline
Perneger et al, 1992 [22] General population studied on 2
occasions
1399 Scr Correlation between Scr and BP
measured >12 years before
Madhavan et al, 1995 [23] Treated hypertensives followed
for >5 years
2125 Scr No significant change in renal function
Secondary analysis of large trials
Participants in the HDFP 10,940 Scr Correlation between baseline BP and
the annual incidence of
hypercreatininemia
Shulman et al, 1989 [24]
Walker et al, 1992 [25] Participants in the MRFJT 361,662 Scr Correlation between baseline BP and
the annual incidence of
hypercreatininemia
a Scr = serum creatinine, DBP diastolic blood pressure, Ccr = creatinine clearance, MBP = mean blood pressure, HDFP = Hypertension
Detection and Followup Program, MRFIT = Multiple Risk Factor Intervention Trial, BP = blood pressure.
"Numbers in brackets refer to reference number.
decline in reciprocal creatinine significantly lower than that seen
when diastolic blood pressure was higher than 90 mm Hg.
However, 44 of the 86 patients whose medical records were
reviewed were black, a group that differs in many respects from
white hypertensive patients. Not only can the pathogenesis of
essential hypertension differ in many respects, but black race also
might be a risk factor for end-stage renal disease independent of
hypertension [16].
Rostand et al used a different approach to the problem [17].
These investigators retrospectively reviewed the records of 181
hypertensive patients who had been followed for at least 12
months (mean, 57.9 months; range, 12 to 174 months). After
excluding from analysis patients with secondary hypertension or
obvious evidence of intrinsic renal disease, 94 patients remained
eligible for analysis. Of these, 14 (15%) had an increase in serum
creatinine greater than 0.4 mg/dl from baseline, regardless of the
degree of blood-pressure control. Thus, renal function deterio-
rated in 16% of the 61 patients whose blood pressure was
apparently well controlled, and in 12% of the patients whose
mean treated diastolic blood pressure exceeded 90 mm Hg. An
increased risk of developing a decline in renal function was noted
in blacks, in elderly patients, in those with a higher number of
missed office visits, and in patients employed as laborers. This
study has been criticized because of its small size and the lack of
convincing evidence that the patients did not have underlying
renal disease [18].
Rosansky et al performed a retrospective study of the relation-
ship between recorded blood pressure data and subsequent
changes in serum creatinine concentration during a mean fol-
lowup of 9.8 years in a cohort of 56 patients with essential
hypertension and 59 control subjects, all participants featuring
normal serum ereatinine levels and "normal" urinalysis results at
entry [19]. The rate of increase in serum creatinine over time was
greater in the subjects with essential hypertension than in the
control subjects (1.08 4.8 versus 0.27 3.5 itmol/liter/year,
mean SD), although the results did not attain statistical
significance. When age, race, body mass index, and a diagnosis of
essential hypertension were entered into a logistic regression
analysis, the hypertensive patients had a significantly greater
increase (P = 0.038) in serum creatinine per year than did the
control subjects. When time-averaged blood pressure also was
included in the analysis, only time-averaged systolic blood pres-
sure was predictive of a change in serum creatinine over time. The
investigators concluded that patients with essential hypertension
initially without clinically detected renal disease had a greater rate
of decline in renal function than did nonhypertensive subjects.
However, the possibility that some hypertensive patients had
clinically undetected renal disease at entry could not be ruled out.
More recently, Innes and colleagues used the U.K. MRC
Glomerulonephritis Registry to detect patients with benign hyper-
tensive nephrosclerosis [20]. Among 7339 biopsies from 20 cen-
ters, 185 biopsies were classified solely as benign hypertensive
nephrosclerosis (2.5%). Sixty-four percent of these patients had a
diastolic blood pressure above 90 mm Hg, and in 9% the diastolic
blood pressure exceeded 120 mm Hg. Serum creatinine was
positively correlated with systolic blood pressure at the time of
biopsy.
Only a few prospective studies have examined the long-term
effect of blood pressure on renal function, in either normotensive
or hypertensive subjects (Table 1). The Baltimore Longitudinal
Study on Aging reported data from 446 subjects, predominantly
white, in whom five or more serial creatinine clearance determi-
nations were obtained over a followup period of 8 years or more
[21]. To obtain a "clinically clean" group for the study of the
effects of blood pressure and age on creatinine clearance, subjects
were divided into three categories: those with possible renal
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disease (118 subjects), those treated with diuretics and/or other
antihypertensive agents (74 subjects), and those who had no
apparent renal disease or who had not received antihypertensive
treatment (254 subjects). Regression analysis revealed a signifi-
cant correlation (P < 0.0001) between the level of mean blood
pressure and the rate of decline in creatinine clearance with time
in years. This relationship remained even when the patients with
renal disease and those taking antihypertensive treatment were
not included. Among individuals without renal disease or antihy-
pertensive treatment, creatinine clearance declined with aging at
a rate of 0.75 0.12 mI/mm/year (mean SEM). In patients with
renal disease, the rate of decline was 1.10 0.23 mi/mm/year, and
in those treated with diuretics and/or other antihypertensive
agents, 0.92 0.32 mi/mm/year. When multiple regression anal-
yses using both mean blood pressure and age as independent
variables were performed, both variables significantly influenced
the rate of decline in creatinine clearance with time. However,
when patients with hypertension (mean blood pressure higher
than 107 mm Hg) were not included, the significant relationship
between mean blood pressure and rate of decline disappeared.
Thus, accelerated loss of renal function was primarily due to the
impact exerted by hypertension [21]. Although this study demon-
strated a faster rate of loss of renal function with aging in
hypertensive subjects, the increase in the rate of decline was too
small to predict evolution to end-stage renal failure.
A large, non-concurrent, cohort longitudinal study was per-
formed by Perneger et a! in a group of 1399 volunteers with
normal to moderately elevated values of both blood pressure and
serum creatinine [22]. The cohort was formed by identifying
subjects who had participated in two independent studies con-
ducted in 1974 and in 1986—1989. Blood pressure measured in
1974 significantly correlated with serum creatinine measured in
1986—1989. The relationship between diastolic blood pressure and
serum creatinine levels measured in 1986—1989 was stronger for
blood pressure values measured in 1974, that is, more than 12
years before, than for values obtained at the time of blood
sampling. This study suggests that blood pressure can predict the
level of renal function, even in individuals whose blood pressure is
in the normotensive range.
In contrast to these findings, a recent, large, prospective study
of 2125 male patients with mild to moderate hypertension dis-
cerned no significant change in serum creatinine over a five-year
followup period [23]. Both initial and final serum creatinine levels
were significantly higher in blacks than in whites, but in both
races, the course of renal function was not obviously related to
blood pressure control, as no association was noted between
blood pressure and changes in serum creatinine over the followup
period. The most powerful determinant of final serum creatinine
was its initial value, and the change in renal function was most
likely a random variation expressed as regression towards the
mean.
Although the question of the relationship between blood
pressure and end-stage renal disease was not originally addressed
in the major intervention trials on mild hypertension, post-hoc
analysis of their results has provided interesting information on
the association between milder forms of hypertension and impair-
ment of renal function (Table 1). In the Hypertension Detection
and Follow-up Program (HDFP), 10,940 hypertensive patients
(8000 with diastolic blood pressures in the range of 90 mm Hg to
104 mm Hg) were randomized to either "referred care" (a group
treated by their own physicians) or "stepped care" (a group
treated according to a standardized protocol). The primary end
point was mortality from all causes, but serum creatinine deter-
minations were obtained at entry and at the end of the second and
fifth years. Secondary analysis of the original data showed a
significant correlation between baseline diastolic blood pressure
and change in serum creatinine over five years [24]. This correla-
tion was independent of the presence of a variety of other factors,
including age, baseline serum creatinine level, diabetes, and
change of diastolic pressure during the followup. Among the
HDFP participants, 8683 had a baseline serum creatinine higher
than or equal to 1.7 mg/dl. In this group, the incidence of a
significant decline in renal function, as defined by a serum
creatinine higher than 2 mg/dl and greater than or equal to 1.25 X
(1 SD) the baseline value, was recorded in 200 participants (2.3%)
during the followup. The decline in renal function was signifi-
cantly higher in blacks compared to whites, in men compared to
women, in older compared to younger patients, and in those with
higher compared to those with lower diastolic pressure at entry.
Known mortality from renal disease for the entire study was only
25 deaths. It is noteworthy that in this analysis, raised serum
creatinine at entry was found to be a predictor of both renal
impairment and a higher incidence of adverse cardiovascular
events [241.
An association between blood pressure and impairment of
renal function also was shown by a secondary analysis of the
361,662 participants in the Multiple Risk Factor Intervention
Trial (MRFIT). When adjusted for age, race, smoking, serum
cholesterol, diabetes, previous myocardial infarction, and income,
both systolic and diastolic hypertension were found to be strong
and independent risk factors for the development of elevated
serum creatinine levels. A cohort of 5524 hypertensive men who
were not receiving antihypertensive therapy at entry was followed
for approximately seven years. White patients showed improved
serum creatinine concentrations with effective antihypertensive
treatment (diastolic blood pressure < 95 mm Hg), whereas in
blacks, the serum creatinine level was not influenced by blood
pressure control [25].
Taken together, these secondary analyses clearly indicate that
hypertension is a risk factor for increased serum creatinine
concentrations, and that hypertensive patients with high serum
creatinine concentrations at entry have an increased risk of a
further deterioration of renal function. These data do not provide
evidence that patients with mild or moderate hypertension and no
underlying renal disease are at increased risk for developing
end-stage renal failure. On the other hand, given the high
prevalence of mild hypertension in the community, and the
incidence of raised serum creatinine concentrations found in the
HDFP, we can project that as many as 70% of the hypertensive
patients with elevated serum creatinine levels in the general
population have only mild hypertension [12].
Mechanisms of hypertension-induced renal damage
As I noted earlier, data indicate that, depending on its severity,
arterial hypertension can initiate progressive renal disease and
can accelerate the more moderate loss of renal function that
occurs with normal aging. In addition, experimental and clinical
data suggest that elevated blood pressure can increase the rate of
progression of intrinsic renal disease.
What is the mechanism by which hypertension damages the
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kidney? The traditional view is that hypertension causes renal
damage as a result of glomerular ischemia and hypoperfusion
induced by progressive narrowing of the lumina of preglomerular
arteries and arterioles. Typically, this is one of the two main
mechanisms (the second being cholesterol crystal microemboliza—
lion) by which atheromatous renovascular disease impairs renal
function [7]. The possibility that a similar mechanism is active in
essential hypertension is supported by observations indicating that
hypertensive patients suffer from renal ischemia due to functional
afferent arteriolar constriction [26]. This increase in renal vascular
tone has been attributed to increased sympathetic activity and/or
to defective sodium-modulated tissue responsiveness to angioten-
sin II [27]. It is interesting to note that renal vasoconstriction
resulting in increased renal vascular resistance, decreased renal
blood flow, and increased filtration fraction also has been dem-
onstrated in normotensive subjects with hypertensive parents.
This finding suggests the presence of an inherited defect in the
control of the renal circulation, a defect operative even at a
pre-hypertensive stage [28].
An alternative hypothesis, based on experimental evidence in
animal models of hypertension, is that in both primary hyperten-
sion and intrinsic renal disease, glomerular capillary hypertension
and hyperperfusion rather than hypoperfusion are the important
factors that lead to glomerular damage and progressive loss of
renal function. According to this hypothesis, the increase in
afferent arteriolar resistance is part of a compensatory mechanism
for preventing transmission of the increased preglomerular pres-
sure to the glomerular capillary network. When this autoregula-
tory response is impaired, the increased systemic pressure is
unrestrictedly transmitted into the glomerular capillary, and thus
glomerular capillary hypertension and hyperperfusion ensue [29].
Increased afferent arteriolar resistance is a prominent hemody-
namic characteristic in the spontaneously hypertensive Okamoto
Aoki rat (SHR), a model with an inherited tendency for hyper-
tension without salt loading. In the early phase of SHR hyperten-
sion, despite very high systemic blood pressure, glomerular cap-
illary pressure remains normal, and renal damage is limited. In the
advanced stage, reduced afferent arteriolar resistance elevates the
glomerular capillary pressure and accelerates renal injury [30].
Evolution to renal disease can be speeded up by uninephrectomy,
which abolishes the protective effect of afferent arteriolar vaso-
constriction in the remaining kidney. These observations have
been used to explain the absence of significant renal disease in
many individuals with long-standing mild to moderate essential
hypertension.
In contrast, in the one-kidney DOCA-salt hypertensive model
of progressive renal disease, the systemic blood pressure is high,
renal vascular resistance is normal or low, and glomcrular capil-
lary pressure is high. This model, as well as other rat models of
salt-induced hypertension (for example, the DahI salt-sensitive rat
model), is characterized by extracellular volume expansion and
low plasma and renal concentrations of renin [31]. On the other
hand, in experimental models of progressive renal disease induced
by removal of renal tissue (for example, uninephrectomy), pre-
glomerular resistance decreases and the glomerular capillary
pressure rises, even when the systemic blood pressure remains
normal. Although the circulatory changes in various models differ
in several respects, increased glomerular capillary pressure seems
to be an important common factor for the development of
progressive renal damage [32].
Increased glomerular capillary pressure has been theorized to
result in increased single-nephron glomerular filtration rate, in-
creased transglomerular passage of proteins, and increased influx
of proteins and other macromolecules into the mesangium. Fur-
ther, some have suggested that the mesangial accumulation of
macromolecules leads to an increase in the mitotic rate of
mesangial cells and of the synthesis of mesangial matrix. This
hypothesis, advanced for the first time by Brenner et alto explain
progression of renal disease independent of the initial injury, has
stimulated numerous studies in the last 15 years [33]. Since
measurement of glomerular capillary pressure in various experi-
mental models has not provided uniform results, other mecha-
nisms, including activation of endothelial cells secondary to
mechanical injury of renal vasculature [34], and nephrotoxicity of
hyperlipidemia analogous to the smooth cell damage that occurs
in systemic atherosclerosis [35], have been proposed as contrib-
uting to glomerular injury. None of these mechanisms has been
convincingly shown to be the key determinant of renal disease
progression, however, and abnormal glomerular passage of mac-
romolecules continues to be the most attractive hypothesis [32].
Growth-promoting peptides in renal tissue, such as insulin-like
growth factor (IGF-l) and epidermal growth factor (EGF),
increase in experimental models of renal ablation and might play
a role both in changes in renal hemodynamics and in modulation
of the proliferation of mesangial cells [36]. Other growth factors,
such as tumor necrosis factor J3 (TNF/3) and platelet-derived
growth factor (PDGF), seem to contribute to the scarring process
of glomerulosclerosis in experimental animals [37]. On the other
hand, further to its potential role in the genesis of glomerular
hypertension and hyperfiltration, angiotensin II recently has been
proposed as contributing to the development and progression of
renal scarring, either through a direct proliferative and fibrogenic
effect, or following modulation of other growth factors, such as
endothelin, TGFJ3, and PDGF [36].
In addition to the increased flux of proteins through the
mesangium, glomerular hyperfiltration might lead to increased
transglomerular passage of proteins into the urinary space and
thus increase urinary protein excretion. An increased urinary
excretion rate of both albumin and 3-microgIobulin has been
reported in patients with inadequately controlled or severe essen-
tial hypertension and decreases after satisfactory blood pressure
control [38, 39]. On the other hand, experimental and clinical
evidence suggests that increased protein traffic into the urinary
space results in exaggerated protein reabsorption by the proximal
tubule with subsequent tubulointerstitial damage. In fact, in
different experimental models, interstitial damage precedes the
development of nephrosclerosis, thus suggesting a causal relation-
ship between tubulointerstitial changes and the development of
sclerotic lesions [401. Whether proteinuria in hypertensive indi-
viduals is merely an indicator of the degree of renal damage or
itself promotes the subsequent evolution of the renal disease
remains controversial.
Renoprotective effect of antihypertensive drugs
That antihypertensive treatment can favorably affect the course
of progressive renal disease has been convincingly demonstrated
in patients with malignant hypertension. As early as 1958, in a
nonrandomized controlled trial in patients with malignant hyper-
tension, Moyer and coworkers reported that in patients treated
with antihypertensive drugs available at that time (a combination
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Table 2. Long-term effects of different classes of antihypertensive agents on renal blood flow
Drug classes RBF" GFR FF RVR AA vs EA
Thiazide diuretics or N" or N N AA = EA
(3-blockers
Propranolol .1. or N or N N I AA = EA
Other j' or N I or N N N AA = EA
a-blockers N N N I AA = EA
Nonspecific vasodilators I or N or N N I AA = EA
ACE inhibitors I or N or N AA < EA
Calcium antagonists
Dihydropyridines j' or N ' or N ' or N I AA> EA
Other I orN
-
, I,orN ? ? ?
a RBF = renal blood flow, GFR = glomerular filtration rate, FF = filtration fraction, RVR = renal vascular resistance, AA = afferent arteriolar tone,
EA = efferent arteriolar tone, 1' = increase, 1. decrease, N no change.
of rauwolfia with ganglionic blocking agents or hydralazine), renal
function remained stable during an average followup period of 28
months. In contrast, untreated patients experienced a deteriora-
tion of 60% from baseline values of BUN, glomerular filtration
rate, and renal plasma flow in only 10 months [411. This informa-
tion clearly is important for the patient population with malignant
hypertension. But the question remains whether adequate arterial
pressure control can exert a protective effect on renal function in
patients with "benign" forms of hypertension.
In the Veterans Administration Cooperative Study and, specif-
ically, in the patients with average diastolic blood pressure ranging
from 90 mm Hg to 114 mm Hg, the incidence of renal disease was
too low to detect significant differences between the treated and
the control group. Thus "renal damage" as a "terminating event"
was reported in only one individual in the control group and in
none in the treated group. Two more cases of "renal damage"
were tabulated as "nonterminating morbid events" in the control
group. "Accelerated hypertension" was recorded in four individ-
uals in the control group and in none in the treated group [61.
Further, no clear-cut advantage of intensive antihypertensive
treatment with regard to renal function was observed in the large
controlled interventional studies on mild and moderate hyperten-
sion [24, 25]. As I mentioned earlier, post-hoc analysis of the
HDFP data on mild hypertension revealed a significant correla-
tion between baseline diastolic blood pressure and changes in
serum creatinine over a five-year followup period. However, the
benefit of "stepped care" on the decline of renal function ap-
peared to be only marginal when compared with the effect
observed in the "referred-care" group (21.7 per 1000 patient-
observation years versus 24.6 per 1000 patient-observation years)
[24]. Similarly, although the white male hypertensive subgroup of
the MRFIT participants whose blood pressure was controlled had
a lower incidence of abnormally high serum creatinirie levels,
irrespective of treatment regimen, no difference could be demon-
strated between the renal effects of "usual care" and "special-
intervention care" [251.
Limited information exists on the potential effects of hyperten-
sion and antihypertensive treatment on renal function in the
elderly. Coope and Warrender conducted a randomized open trial
without placehos in 884 hypertensive patients, aged 60 to 79 years,
recruited from 13 general practices in England and Wales [42].
Mean values (± SD) for systolic and diastolic blood pressure were
196.7 (± 16.7) mm Hg and 99.7 (± 12.0) mm Hg, respectively, in
the treated group, and 196.1 (± 15.6) mm Hg and 98.0 (± 11.8)
mm Hg, respectively, in the control group. Patients on active
treatment were given atenolol, bendrofluazide, and methyldopa in
a stepwise combination. Patients not effectively treated with this
regimen were treated with "any recognized therapy rather than
remain untreated." The serum creatinine levels at the end of a
two-year followup period were significantly lower in the treated
group than in the control group, but only one death from
hypertension-related renal disease was recorded in the control
group versus none in the treated group. The European Working
Party on High Blood Pressure in the Elderly (EWPHE) trial was
a randomized, double-blind, placebo-controlled study of the effect
of antihypertensive treatment on morbidity and mortality in 840
hypertensive patients over the age of 60 [31. Patients in the
actively treated group received hydrochlorothiazide in combina-
tion with triamterene as first-line treatment; methyldopa was
added in 35% of patients when blood pressure remained high.
Measurement of serum creatinine at entry and at three-month
intervals throughout the trial revealed a decline in renal function
in the treated group, whereas no change was noted in the placebo
group. Five patients receiving active treatment and one receiving
a placebo were withdrawn according to the protocol criteria
because of an increase in serum creatinine of 100% or more. The
rise in serum creatinine in the treated group correlated with the
decrease in systolic pressure, thus suggesting that renal impair-
ment in elderly hypertensive patients is the result of antihyper-
tensive treatment rather than the consequence of elevated blood
pressure [43].
In considering the renal effects of antihypertensive treatment,
several important questions arise: Should the immediate or
medium-term renal effects of antihypertensive treatment be dis-
tinguished from its long-term effects on renal prognosis? Is the
potentially protective effect of antihypertensive therapy deter-
mined by changes in the systemic blood pressure? Can antihyper-
tensive therapy delay the rate of progression of an underlying
renal disease? Does the ability of antihypertensive therapy to
protect the kidney depend on the particular antihypertensive
agent used to lower blood pressure? Lastly, what target blood
pressure is necessary to preserve renal function?
Several studies have provided evidence that various antihyper-
tensive agents exert disparate short-term or prolonged effects on
renal hemodynamics (Table 2). Initiation of treatment with
thiazide diuretics significantly decreases renal blood flow and
produces a modest decrease in glomerular filtration rate along
with an increase in renal vascular resistance and in filtration
fraction. After several months of treatment, both renal blood flow
and glomerular filtration rate tend to rise slightly above baseline,
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while renal vascular resistance decreases consistently below base-
line without a noticeable effect on filtration fraction. Therefore, in
the long term, thiazide diuretics appear to exert a balanced
vasodilating effect both on afferent and efferent arterioles [44],
Available data indicate that acute and prolonged administration
of propranolol increases renal vascular resistance and modestly
decreases renal blood flow and glomerular filtration rate. Al-
though the exact mechanism by which this agent exerts its action
on renal vasculature remains unclear, the fall in renal perfusion
seems to be, at least in part, independent of the effect of beta
blockade on cardiac output or systemic vascular resistance. That
filtration fraction remains unaffected suggests a proportional
change in both pre-glomerular and post-glomerular vascular tone
[45]. Conflicting results have been reported with other beta-
blocking agents. Thus nadolol and tertatolol seem to increase
both renal blood flow and glomerular filtration rate during acute
administration. This effect tends to persist during long-term
treatment with tertatolol but not with nadolol. Finally, renal
hemodynamics remain unaffected during long-term therapy with
31-selective beta blockers or beta blockers with intrinsic sympa-
thomimetic activity [46]. On the other hand, although cw1-adren-
ergic blockers and direct vasodilators both lower renal vascular
resistance, administration of a1-adrenergic blockers is character-
ized by unchanged renal blood flow and glomerular filtration rate,
while changes in renal perfusion and filtration during treatment
with direct vasodilators seem to depend on the extent of the fall in
blood pressure [47]. It is noteworthy that in their retrospective
analysis of data from patients with progressive renal disease,
Brazy and Fitzwilliam found no evidence that the effect of
antihypertensive treatment with a beta blocker (usually propran-
olol or atenolol), prazosin, a calcium antagonist (usually vera-
pamil or nifedipine), or clonidine on the slope of the reciprocal of
serum creatinine versus time was influenced by the type of
antihypertensive agent. The only exception was diuretics that,
when used alone, resulted in a significantly faster rate of change in
reciprocal creatinine than did treatment with other antihyperten-
sive medications [16].
Of the more recently introduced antihypertensive agents,
angiotensin-converting enzyme (ACE) inhibitors decrease renal
vascular resistance and increase renal blood flow and glomerular
filtration rate in normal subjects on a restricted sodium intake [48]
and in patients with essential hypertension [49]. More impor-
tantly, experimental evidence suggests that by preferentially acting
on the efferent arteriole, ACE inhibitors can reduce intraglomeru-
lar pressure disproportionate to the decrease in systemic blood
pressure. In addition, through their depressing effect on efferent
arteriolar resistance, ACE inhibitors can dissociate renal blood
flow from glomerular filtration rate. Thus, glomerular filtration
pressure might remain unchanged in the presence of increased
renal blood flow, and as a consequence filtration fraction may be
reduced [491. On the other hand, when renal perfusion pressure is
decreased, as in the case of bilateral renal artery stenosis or renal
artery stcnosis in a solitary kidney, administration of ACE inhib-
itors can impair the autoregulatory effect of angiotensin-mediated
efferent arteriolar constriction, thus leading to deterioration of
renal function [50].
Because ACE inhibitors lower not only systemic blood pres-
sure, but glomerular capillary pressure as well, these agents might
be more effective than other forms of antihypertensive treatment
in preventing the progression of renal damage. This view was
initially supported by animal studies in which ACE inhibitors were
compared with a combination of reserpine, hydralazine, and
hydrochiorothiazide in arresting progressive renal disease associ-
ated with systemic hypertension. Despite producing an equal
reduction in systemic blood pressure, only ACE inhibitors re-
duced intraglomerular pressure and prevented progressive gb-
merular injury [51]. Subsequent evidence has suggested that the
particular advantage of ACE inhibitors in lowering intraglomeru-
lar pressure and in preventing progression of renal damage cannot
be demonstrated in all experimental models of progressive neph-
rosclerosis [52, 53]. Nevertheless, a wide acceptance of the
concept of the importance of intraglomerular pressure rather than
systemic blood pressure in the pathogenesis of progressive renal
injury is currently prevailing. This concept is best exemplified by
investigations in diabetic nephropathy.
Diabetic nephropathy has long been considered a model of
predictable renal disease in which progression of renal injury is
influenced by changes in intrarenal hemodynamics. Lowering of
arterial pressure restricts gbomerular sclerosis in animal models of
diabetes mellitus [54], and adequate control of hypertension
delays the progression of renal disease in patients with diabetic
nephropathy, even in the absence of a change in metabolic control
of diabetes [55]. A constant finding in both experimental strepto-
zotocin-induced diabetes mellitus and insulin-dependent diabetes
mellitus (IDDM) in humans is the marked glomerular hyperfil-
tration that characterizes the early stages before the onset of overt
renal disease. In experimental diabetes, gbomerular hyperfiltration
ensues from an increased glomerular capillary hydraulic pressure
caused by a reduction in preglomerular resistance proportionally
greater than the reduction in post-glomerular arteriolar tone.
Through their action on post-glomerular arterioles, ACE inhibi-
tors prevent the development of glomerular hypertension and
exert a remarkable protective effect against the development of
renal damage [56]. However, evidence indicates that, at least in
this model, the renoprotective effect of ACE inhibitors can be
demonstrated only when these agents are administered early in
the course of the disease. After proteinuria has developed, ACE
inhibitors are no longer renoprotective, although they can effec-
tively control systemic blood pressure [57]. A beneficial effect of
ACE inhibitors on renal function in patients with IDDM and
nephropathy was first reported in 1986 [58]. Subsequent studies
have demonstrated that these agents can (1) postpone the devel-
opment of diabetic nephropathy in normotensive patients with
IDDM and persistent microalbuminuria, (2) confer an antipro-
teinuric effect independent of that attributable to their blood-
pressure-lowering effect, and (3) protect against deterioration in
renal function more effectively than does blood pressure control
alone [59—63]. On the basis of these findings, a consensus has
arisen that ACE inhibitors should be used as part of an antihy-
pertensive regimen in patients with IDDM, and also that ACE
inhibitors should be initiated in normotensive patients with
IDDM who have persistent microalbuminuria or Overt proteinuria
[64].
Calcium antagonists represent a heterogeneous group of agents
that inhibit calcium entry into cardiac cells and vascular smooth
muscle cells. Indirect evidence as well as direct observations using
the model of isolated perfused hydronephrotic kidney developed
by Loutzenhiser and Epstein [65] have indicated that calcium
antagonists preferentially dilate the afferent arteriole. In some
studies in humans, dihydropyridine calcium antagonists have
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increased renal blood flow and glomerular filtration rate with little
effect or a slight increase in filtration fraction [66]. Other studies
failed to demonstrate any effect of these agents on renal hemo-
dynamics in humans [45]. On the other hand, no uniform renal
effects have been reported with verapamil and diltiazem in
patients with essential hypertension and normal renal function
[67].
Because calcium antagonists preferentially reduce preglomeru-
lar arteriolar resistance, theoretically these agents increase gb-
merular pressure, thus contributing to disease progression. This
hypothesis is supported by the finding of persistent glomerular
hypertension during treatment with nifedipine in rats with strep-
tozotocin-induced diabetes [68]. Several clinical studies have
compared ACE inhibitors and calcium antagonists in normoten-
sive and hypertensive patients with incipient or overt diabetic
nephropathy [69]. In the sole study of normotensive IDDM
patients with incipient diabetic nephropathy, Mimran et al re-
ported that captopril consistently reduced microalbuminuria,
whereas nifedipine increased urinary albumin excretion [591. In
contrast, in hypertensive patients with non-insulin-dependent
diabetes mellitus (NIDDM), both enalapril and nicardipine (an-
other dihydropyridine derivative) were equally effective in lower-
ing blood pressure and in reducing albuminuria [70]. In NIDDM
patients, however, microalbuminuria can be secondary to essential
hypertension or unrelated renal disease rather than to diabetes.
On the other hand, when the ACE inhibitor lisinopril was
compared to the calcium antagonists verapamil [71] or diltiazem
[72], both lisinopril and the calcium antagonists reduced protein-
uria to the same extent.
The results of studies on diabetic nephropathy raise two
additional questions: First, does the difference in antiproteinuric
action between ACE inhibitors and calcium antagonists mean that
ACE inhibitors are more effective than calcium antagonists in
preventing renal injury or delaying the evolution of renal disease?
Second, is the potential renoprotective advantage of ACE inhib-
itors restricted to diabetic patients, or can this effect be extrapo-
lated to non-diabetic patients with renal disease? Clinical evi-
dence has led many authors to propose that urinary protein
excretion is a valid predictor of the progression of renal disease
[73, 74]. In addition, as I already mentioned, proteinuria has been
claimed not only to be an indicator of the degree of renal damage,
but also to play an important causal role [32]. In a relatively recent
clinical trial in patients with established diabetic nephropathy, a
prolonged decrease in proteinuria by enalapril could not be shown
to be associated with an attenuation in the progression of renal
disease [75]. Thus, although ACE inhibition therapy, but not
conventional or diuretic therapy, decreased urinary protein excre-
tion, the rate of decline of glomerular filtration rate during the
first 18 months did not differ between the two treatment groups.
Certain studies in humans have suggested that ACE inhibitors
confer better renoprotection than do calcium antagonists or the
so-called conventional antihypertensive treatments [68]. However,
in a four-year, multicenter, prospective, randomized trial compris-
ing 142 patients with established chronic renal failure, Zucchelli et
al [76] found that whereas more effective control of hypertension
with either captopril or slow-release nifedipine retarded the
progression of renal insufficiency, the reduction in the progression
rate induced by captopril was no greater than that of nifedipine.
Several meta-analyses have attempted to overcome the limita-
tions originating from small sample size in numerous reports on
the long-term effects of antihypertensive drugs on proteinuria and
renal function, both in diabetic and nondiabetic patients with
renal disease. Recently, Gansevoort et al examined the results of
41 trials in which the antiproteinuric effect of an ACE inhibitor
was directly compared with that of another aritihypertensive
agent, irrespective of the renal disease underlying the proteinuria
[77]. A total of 1124 patients were included in the articles
subjected to meta-analysis. About one-half of them (566) had
diabetic renal disease; the rest had hypertensive nephropathy or
primary glomerular disease. The meta-analysis clearly showed
that ACE inhibition conferred an antiproteinuric effect signifi-
cantly greater than that of their comparator drug and beyond that
attributable to their antihypertensive effect. Thus, the mean
antiproteinuric effect of an ACE inhibitor (captopril, enalapril,
lisinopril, ramipril, cilazapril, benazepril, perindopril, spirapril)
was —39.9% (95% confidence interval —42.8% to —36.8%), while
that of the compared drugs (dihydropyridine compounds, vera-
pamil, diltiazem, beta blockers, hydrochborothiazide, and other
drugs) was only —17.0% (95% confidence intervals —19.0% to
—15.1%). In contrast, the blood-pressure-lowering effect was
equal (—12.0% versus —11.2%). Among calcium antagonists,
nifedipine had the least effect on proteinuria, and no differences
existed among various classes of compared drugs. A significantly
greater antiproteinuric effect of compared drugs was found in
diabetic patients, but this finding coincided with a greater antihy-
pertensive effect in this group.
Maki and coworkers conducted a meta-analysis of the results of
84 clinical trials comparing the effects of different antihyperten-
sive agents on blood pressure, proteinuria, and renal hemodynam-
ics in diabetic patients with and without nephropathy and patients
with essential hypertension or primary renal disease [78]. Only
investigations with followup times of at least six months were
included in the analysis. In 14 randomized controlled trials, 12 of
which included patients with diabetes, ACE inhibition reduced
proteinuria and improved gbomerular filtration rate compared to
control. Both effects were remarkably similar in diabetic and
nondiabetic patients. Furthermore, the pooled results of three
randomized controlled trials with nondihydropyridine calcium
antagonists showed a decline in proteinuria and a relative im-
provement in glomerular filtration rate. In contrast, dihydropyri-
dine calcium antagonists and most other agents had no apparent
effect on proteinuria, and dihydropyridine calcium antagonists
had no beneficial effect on gbomerular filtration rate in diabetic
patients. In a multivariate analysis of pooled controlled and
uncontrolled trials, blood pressure reduction due to antihyperten-
sive therapy decreased proteinuria, but ACE inhibitors and
nondihydropyridine calcium antagonists were associated with
additional declines in proteinuria that were independent of blood
pressure changes and the presence of diabetes. In addition to the
decrease in proteinuria, blood pressure reduction yielded a rela-
tive improvement in glomerular filtration rate that was similar for
most antihypertensive agents, including ACE inhibitors, and
similar in diabetic and nondiabetic patients. However, among
diabetic patients, glomerular filtration rate tended to be relatively
lower with dihydropyridine calcium antagonists. The results of a
second exploratory regression analysis, which included multiple
possible interactions with patient and study characteristics, sug-
gested that the beneficial effects of ACE inhibition on renal
function might be relatively less in men and in older patients.
The need for redefinition of a target blood pressure that would
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preserve renal function was first suggested by Klahr in 1989 [79].
More recently, the Joint National Committee for the Detection,
Evaluation, and Treatment of High Blood Pressure recommended
a target blood pressure of 130/85 mm Hg or less (instead of the
usual target of less than 140/90 mm Hg) for patients with renal
disease [80]. The hypothesis that the maintenance of blood
pressure at a level below that usually recommended retards the
progression of renal disease was essentially tested by the Modifi-
cation of Diet in Renal Disease (MDRD) Study [81]. This study
compared the rates of decline in glomerular filtration rate in 840
patients with various chronic renal diseases who were randomly
assigned to either a usual or a low blood pressure goal (mean
blood pressure, 107 mm Hg or 92 mm Hg). In the patients with a
baseline glomerular filtration rate ranging from 25 mi/mm X 1.73
m2 to 55 mI/mm x 1.73 m2 (study 1), the intent-to-treat analysis
showed that the mean decline in the glomerular filtration rate was
more rapid during the first four months after randomization, but
slower thereafter, in the group with low blood pressure as
compared to the group with usual blood pressure. In contrast, in
patients with a baseline glomerular filtration rate of 13 ml!min x
1.73 m2 to 24 mi/mm x 1.73 m2 (study 2), the decline in renal
function did not differ between the two groups. The MDRD study
also supported the view that proteinuria is an independent risk
factor for the progression of renal disease. Thus, in both studies 1
and 2, the lower blood pressure significantly reduced proteinuria
during the first four months of followup, and this reduction
correlated with a slower decline in glomerular filtration rate. The
authors suggested that proteinuria should be considered when a
target blood pressure is determined in patients with renal disease.
They recommended a target mean pressure of less than 98 mm Hg
(130/80 mm Hg) in patients with proteinuria of 0.25 to 1.0 g/day,
and a target mean blood pressure of less than 92 mm Hg (125/75
mm Hg) for those with proteinuria of more than 1 glday [82]. It is
obvious that such a revolutionary approach cannot be easily
adopted without further confirmation of these findings in future
studies.
Conclusion
Despite a considerably high incidence of end-stage renal dis-
ease presumably due to hypertension, the individual risk of renal
impairment in patients with mild to moderate hypertension seems
to be low, particularly when compared to their risk of developing
other target-organ damage. Epidemiologic and retrospective stud-
ies suggest that lower blood pressure levels are associated with a
slower decline of renal function with age, and with a slower
progression of underlying renal disease. In addition to adequate
blood pressure control, baseline characteristics—such as race,
age, and severity of hypertension—influence the rate of deterio-
ration of renal function. In diabetic patients with or without overt
nephropathy, as well as in patients with essential hypertension or
primary renal disease, antihypertensive therapy, irrespective of
the agent used to lower blood pressure, exerts beneficial effects on
proteinuria and renal function that are proportional to blood
pressure reduction, in addition, ACE inhibitors and possibly
nondihydropyridine calcium antagonists might have further ben-
eficial effects on proteinuria that are independent of blood
pressure reduction. Any advantage in decreasing proteinuria does
not necessarily imply a better effect on the rate of progression of
renal disease. On the other hand, the reduction in cardiovascular
risk from treating hypertension is much more evident than the
reduction in the risk of developing renal failure. As Bauer pointed
out [64], since about one-half of the patients on renal replacement
therapy die from cardiovascular causes, the choice of drug therapy
for an individual hypertensive patient with renal disease should be
primarily based on its ability to reduce adverse cardiovascular
events and to contribute to the treatment of concomitant cardio-
vascular disease rather than on any potential advantage for the
protection of renal function.
Questions and answers
DR. NIcoLAos E. MADIAs (Chief Division of Nephrology, New
England Medical Center, Boston, Massachusetts, USA): We are
faced with a paradox: On the one hand, so-called benign nephro-
sclerosis is one of the most prevalent diagnoses in patients starting
renal replacement therapy. On the other hand, most clinicians
believe that nonmalignant chronic hypertension only rarely leads
to substantial renal dysfunction. Of course, as you noted, given the
enormity of the hypertensive population, even a very small risk of
developing renal failure translates into a substantial number of
patients with end-stage renal disease. With regard to the low
incidence of hypercreatininemia in the HDFP and MRFIT stud-
ies, one could argue that because of the relatively slow rate of
progression, followup greater than five to seven years might be
required to detect the development of renal dysfunction in many
patients. Further, you mentioned that another underlying renal
disease might conspire with hypertension to result in end-stage
renal disease. Could you reflect a bit more on these possibilities?
DR. MOUNTOKALAKJS: Because of the lack of criteria for the
diagnosis of hypertensive nephroscierosis, a considerable propor-
tion of the patients with advanced renal disease who are classified
under the headings of "hypertension" or "nephrosclerosis" prob-
ably are misdiagnosed. The ambiguity in diagnosis is also indi-
cated by the great variation in the incidence of end-stage renal
disease due to a presumed diagnosis of hypertension-associated
nephrosclerosis among the registry data of different countries.
Uncertainty about the cause of end-stage renal disease seems to
prompt a current "fashionable" diagnosis, so that the number of
cases of end-stage renal disease of unknown cause is lessened in
registry statistics. This approach might explain why chronic gb-
merulonephritis has been overdiagnosed in the past, and why
pyelonephritis, once considered one of the chief causes of end-
stage renal disease, is now underrated as a cause of chronic renal
failure in national registries, both in Europe and the U.S. Like
most clinicians, I very rarely see a hypertensive patient who
progresses to renal insufficiency; even then, I cannot be certain
whether this particular patient has hypertension-related glomer-
ulosclerosis or atheromatous disease of the renal artery, or even
some other coexisting renal disease, such as chronic glomerulo-
nephritis. On the other hand, as you also pointed out, because of
the high prevalence of essential hypertension, the risk of renal
impairment in the general hypertensive population might be high
despite a low individual risk. Therefore, regardless of the ambi-
guity concerning the true incidence of so-called hypertensive
nephrosclerosis, it appears that hypertension has a substantial role
as a cause of end-stage renal disease.
DR. MADIAS: A certain fraction of patients with essential
hypertension, probably on the order of 50%, feature increased
sodium-hydrogen exchanger (NHE) activity in their blood cells
[83]. In hypertensive patients, this phenotype (or increased sodi-
um-lithium countertransport) is associated with a number of
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cardiorenal abnormalities [83, 84]. In addition, an overactive
NHE is found in patients with type-I or type-lI diabetes and
nephropathy but not in those without nephropathy [85, 86]. My
question is, do patients with advanced renal dysfunction due to
presumed benign nephrosclerosis have an overexpressed NHE
activity compared with otherwise matched patients with essential
hypertension?
DR. MouNToc&iius: To my knowledge, no such information
exists in the literature. As you mentioned, increased erythrocyte
NHE activity has long been considered a genetic marker for
predisposition to hypertension. In addition, several mechanisms
have been proposed by which increased NHE activity in cells
other than blood cells could be involved in the pathogenesis of
essential hypertension. In particular, it has been speculated that
increased NHE activity in the renal proximal tubule could in-
crease sodium reabsorption and thus induce volume expansion. In
this case, the kidney would play the role of the "villain" rather
than the "victim." On the other hand, salt sensitivity has been
associated with a more rapid progression of renal damage in
hypertensive patients [87]. Therefore your suggestion of a causal
link between increased activity of the sodium-hydrogen exchanger
and the development of hypertensive nephrosclerosis seems very
attractive.
DR. JOHN T. HARRINGTON (Dean, Tufts University School of
Medicine, Boston): In patients with essential hypertension, do
histopathologic changes correlate with simultaneous measures of
renal function? Should we be performing renal biopsies in pa-
tients with moderate renal insufficiency to detect diagnoses other
than hypertensive nephrosclerosis?
DR. MouNToictxIs: One of the studies I cited [201 used the
U.K. MRC Glomerulonephritis Registry to determine clinical
features of biopsy-proven benign nephrosclerosis. The most
marked finding in this study was that significant proteinuria was
common in patients with benign nephrosclerosis; in a number of
them, it reached the nephrotic range. The majority of patients had
a raised serum creatinine level, but this finding might reflect
selection for biopsy. I believe that data from Zucchelli and
Zuccala [7] have documented the value of renal biopsy and of
imaging of the aorta and renal arteries in distinguishing hyper-
tensive nephrosclerosis from atheromatous renovascular disease
or other intrinsic renal diseases when that diagnosis is doubtful on
clinical grounds. However, histologic interpretation of biopsy
material from hypertensive patients is quite difficult.
DR. H. G. RENNKE (Director, Renal Pathology and Electron
Microscopy Laboratory, Brigham and Women's Hospital, Boston): I
would like to make a short comment about terminology. The term
"nephrosclerosis" is vague, and its use should be avoided; it
literally means scarring of the kidney. We need to be more precise
when referring to lesions that are exacerbated by systemic hyper-
tension [88]. An elevation of the arterial blood pressure to levels
considered benign are, in general, associated with a reduction in
the number of smooth muscle cells in the media of arteries and
arterioles and with accumulation of connective tissue at these
sites. This process is referred to as arterial and arteriolar sclerosis.
There is also deposition of amorphous hyaline material in the
subintima of arterioles derived from the plasma, or arteriolar
hyalinosis. These changes are not specific, as they are also part of
the normal aging process. The consequences of these vascular
changes to the nephron are glomerular hypoperfusion and obso-
lescence of the capillary tuft (glomerulosclerosis), atrophy of the
metabolically more demanding tubular segments, thickening of
the tubular basement membranes, and accumulation of interstitial
collagen. Systemic hypertension in the malignant range results in
a proliferative arteriopathy. The early changes in small arteries
and arterioles consist of fibrinoid necrosis of the wall, a lesion that
is identical to that seen in thrombotic angiopathies. This initial
phase is followed by proliferation of cells in the vascular wall and
deposition of collagen matrix, which results in concentric layers of
tissue and the characteristic "onion-skin" appearance of the vessel
[891. Many of these changes, but especially the glomerular and
tubulo-interstitial damage, can and should be assessed quantita-
tively or semi-quantitatively by morphometric techniques.
DR. MADIAS: Let me pursue a little more the theme of the
pathogenesis of benign nephrosclerosis. A very interesting issue
that has been raised is the possible relationship between low birth
weight and the development of hypertension and renal disease.
The offspring of rats fed a low-protein diet have a low birth weight
and a small number of functioning nephrons, and they are prone
to developing hypertension and renal glomerulosclerosis [90, 91].
Also, human studies have related low birth weight and increased
risk of hypertension [92, 93]. These data have led to the hypothesis
that malnutrition of the mother might cause underdevelopment of
the fetal kidneys, with subsequent adverse sequelae. For socio-
economic reasons, malnutrition in the U.S. is likely to be more
common in blacks; indeed, black women are more likely to give
birth to small-for-gestational-age infants [94]. This observation
might have relevance to the fact that, as you noted, blacks have a
several-fold greater risk of developing hypertension-induced end-
stage renal disease, even if their blood pressure is well controlled.
My question is, have studies correlated renal disease in patients
who have essential hypertension with body weight at birth?
DR. MOUNTOKALAKIS: I am not aware of any such study.
DR. GREGORY VOSNIDES (Laikon General Hospita4 Athens,
Greece): I have two questions for Dr. Mountokalakis. The first is
an extension of the question asked by Dr. Madias. What criteria
do you use during teaching rounds to tell your students that in a
patient with hypertension and renal insufficiency, hypertension is
the etiologic factor of renal functional impairment? My second
question is: Does a sudden fall in blood pressure induced by
antihypertensive drugs have any long-term deleterious effects on
renal function, particularly in elderly hypertensive patients?
DR. MOUNTOKALAKIS: I am inclined to attribute renal disease to
high blood pressure when I see a patient with a history of
long-standing hypertension, small kidneys, and no evidence of
pre-existing intrinsic renal disease, particularly when other target-
organ damage is present, such as retinopathy and cardiac hyper-
trophy. However, this is still a presumptive diagnosis. As far as
your second question is concerned, the European Working Party
on High Blood Pressure in the Elderly trial showed a deteriora-
tion of renal function during antihypertensive treatment in pa-
tients older than 60 years [43], but the incidence of impaired renal
function was much less than that of other cardiovascular sequelae
in this trial. We are now convinced by the results of the large
prospective placebo-controlled trials in the elderly [95—97], that
the benefits of antihypertensive treatment in older patients with
hypertension, in terms of cardiovascular morbidity and mortality,
as well as of total mortality, are of at least the same magnitude as
the benefits of treatment in younger hypertensive patients. There-
fore, the need to treat elderly hypertensive patients is obvious with
regard to decreasing cardiovascular morbidity and mortality. It is
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important, of course, in this age group, to initiate treatment with
low doses and only slowly increase them.
DR. MADIAS: It is indeed true that the Systolic Hypertension in
the Elderly Program (SHEP) and other trials have shown the
benefit and safety of reducing systolic and diastolic hypertension
in the elderly. However, given the blood pressure goal that you
mentioned, are you concerned about a J-curve effect of diastolic
blood pressure treatment, especially in patients with ischemic
heart disease and left-ventricular hypertrophy?
DR. MouNTocLIs: In the SHEP study, cardiac events were
not stratified according to diastolic blood pressure during treat-
ment. Thus, it is not possible to determine whether a J-shaped
curve of cardiovascular morbidity and mortality existed in this
particular trial. In any case, the J-curve issue has been disputed
recently, and we should wait for the final results of the Hyperten-
sion Optimal Treatment (HOT) study before we draw definite
conclusions. Nevertheless, I would be very reluctant to advocate
the target blood pressure of 125/75 mm Hg proposed by the
MDRD study [81] in patients with heavy proteinuria, particularly
because hypovolemia is a common feature in the nephrotic
syndrome.
DR. D. SYMVOULIDOU (University of Athens Medical School,
Hippokration Hospital, Athens): You mentioned the protective
effect of ACE inhibitors on renal function. The MDRD study and
other studies suggest that dietary protein restriction can slow the
progression of renal disease by about 30%. How would you
comment on the relative efficacy of these two modes of interven-
tion? Is it possible that their effect is additive, and would you favor
the use of either or both of them to delay progression of renal
disease, irrespective of hypertension?
DR. MouNTocLAK1s: In fact, the results of the MDRD Study
[82] as well as of other previous studies [98] suggest that dietary
protein restriction can slow the progression of renal disease.
However, this benefit seems to be small, and in any case, smaller
than that of antihypertensive treatment. Moreover, adherence to
a low-protein diet is not easy. Even in studies that have examined
the effect of protein restriction on the progression of renal
disease, despite regular followup by skilled dietitians, protein
intake was consistently higher than that prescribed. On the other
hand, the results of a recent Italian multicenter, prospective
randomized trial offer little, if any, support to the view that a
low-protein diet can delay deterioration of renal function more
effectively than can a controlled-protein diet [99]. Future studies
are certainly needed to compare the long-term effects of com-
bined low-protein diet and antihypertensive treatment versus
antihypertensive therapy alone.
DR. MADIAS: Hyperuricemia has been suggested as an indicator
of early renal damage in patients with essential hypertension.
Could you please comment on this issue? Also, what is the
prognostic significance of microalbuminuria in patients with es-
sential hypertension?
DR. MOUNTOKALAKIS: Hyperuricen-iia has been proposed as
both a predictor of hypertension and an indicator of renal damage
in hypertensive patients. Messerli et al, for example, have shown
that hyperuricemic patients have a lower renal blood flow and
higher renal and systemic vascular resistance [100]. But the wide
variation of normal values and the variety of factors that can
influence serum uric acid levels make it difficult to assess the
clinical significance of serum uric acid in the individual hyperten-
sive patient. On the other hand, the degree of proteinuria in
hypertensive patients appears to increase with the level of blood
pressure, and microalbuminuria has been associated with a
greater prevalence of cardiovascular disease in hypertension. It is
unclear whether the presence of microalbuminuria in patients
with essential hypertension predicts either the development of
overt proteinuria or the decline in renal function.
DR. D. GREKAS (AHEPA University Hospita4 Thessaloniki,
Greece): According to recent data, the incidence of nephroscle-
rosis and end-stage renal disease is higher in the U.S. than in
Europe. Can you explain this difference?
DR. M0uNT0KALAJU5: The increased incidence of both hyper-
tension and nephrosclerosis in blacks partially explains this dis-
parity. In addition, for some reason, American nephrologists seem
to be more eager than European nephrologists to designate
patients who have end-stage renal disease and hypertension with
the label of hypertensive nephrosclerosis.
DR. MADIAS: We should not kid ourselves that we have been
particularly effective in controlling hypertension in the United
States. No doubt progress has been made. Yet, despite all the
educational programs, the latest survey in the U.S., the Third
National Health and Nutrition Examination Survey (NHANES
III), estimated that hypertension was controlled in only 24% of
non-Hispanic whites and blacks and in only 14% of Mexican-
Americans [1011. Have data emerged from Europe and Greece
regarding the fraction of the hypertensive population whose blood
pressure is controlled?
DR. MOUNTOKALAKIS: The Starnberg Study on Epidemiology of
Parkinsonism and Hypertension in the Elderly (STEPHY)
showed similar figures for Europe in 1994 [102]. Of the total
hypertensive population, 54% were treated and only 22% were
controlled. In Greece, although we lack exact data, we can
estimate that blood pressure is controlled in only one-third of the
treated patients. I believe that a great part of our incompetence is
due to our failure to appreciate the importance of patient
education.
DR. D. S. EMMANOUEL (University of Crete Medical School,
Heraklion, Greece): My question refers to a practical issue that
relates to both Dr. Madias' comment concerning compliance and
also to Bauer's statement in the 1995 paper you quoted [64]. What
are the practical guidelines for blood pressure goals, and how do
these guidelines relate to ambulatory blood pressure monitoring'?
DR. Mour'roKALAKIs: All that we know about blood pressure
control in terms of decreasing cardiovascular morbidity and
mortality is based on readings taken in the clinic. Ambulatory
blood pressure monitoring is an interesting research technique,
but we have no prognostic standards regarding the lowest level of
blood pressure requiring treatment or the levels that we should
aim to achieve with treatment. Therefore, our therapeutic deci-
sions are based on clinic-obtained blood pressure measurements.
Available evidence suggests that we should try to reduce systolic
blood pressure to less than 140 mm Hg and diastolic blood
pressure to less than 90 mm Hg. In patients with diabetes and/or
renal disease, we probably should reduce blood pressure even
further, that is, on the order of 120—130/80 mm Hg.
DR. F. CHRISTIDOU (2nd IKA General Hospital, Thessaloniki):
Have any studies correlated the degree of retinopathy due to
hypertension with the degree of nephrosclerosis? Can a patient
with hypertension-associated nephrosclerosis not have any retinal
damage?
DR. MOUNTOKALAKIS: I am not aware of such a study. Although
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the assessment of hypertensive retinopathy is an integral part of
the examination of the hypertensive patient, a study published in
the Lancet demonstrated that in patients with mild to moderate
hypertension, retinal features showed little relation to either the
clinic-obtained or ambulatory blood pressure, whereas other
parameters, such as microalbuminuria, were closely related to the
severity of hypertension [103]. The authors also demonstrated
considerable interobserver differences in the interpretation of the
ophthalmoscopic findings. Thus, it is not easy to conduct studies
relating retinal changes to other target-organ damage in hyper-
tensive patients. We should remember that hypertension is not the
sole determinant of retinal artery sclerosis in hypertensive reti-
nopathy. Retinal artery sclerosis also results from normal aging
and relates to the presence of other ocular and systemic disorders.
DR. A. LASARIDIS (AHEPA University Hospital, Thessaloniki): If
you believe that the predictive value of albuminuria in the
progression of renal disease is lower after antihypertensive ther-
apy than when applying baseline values, what is the meaning of
the studies showing different effects of various drugs on albumin-
uria?
DR. MOUNTOKALAKIS: In cases of considerable urinary protein
loss, there is an obvious benefit from decreasing proteinuria itself.
On the other hand, although proteinuria correlates positively with
the rate of deterioration of renal function, it is unclear whether
the proteinuria simply reflects more active underlying renal
disease or is causally related to the progression of renal damage.
The recent Northern Italian Cooperative Study indicated that
renal survival was longer in patients whose proteinuria decreased
either spontaneously or because of antihypertensive treatment
[991- Thus, lowering proteinuria might prevent progressive loss of
renal function.
DR. J. BOLETIS (Laikon General Hospital): You gave us data on
the various degrees of renal protection offered by different
calcium-channel blockers. Does the same apply to the various
ACE inhibitors?
DR. MOUNTOKALAKIS: In the meta-analysis by Maki et al, most
ACE inhibitors had similar effects [78]. However, lisinopril, which
was examined in fewer studies (5 versus 22with captopril and 22
with enalapril), failed to improve glomerular filtration rate.
Although possible differences in renal tissue uptake among the
different ACE inhibitors might explain the apparent failure of
lisinopril to improve renal function [104], further studies directly
comparing lisinopril with other ACE inhibitors are needed to
clarify this issue. Also, in two of the studies included in the
meta-analysis, lisinopril proved beneficial. A recent study exam-
ined the effect of benazepril, another nonsulfhydryl ACE inhibi-
tor, on the progression of renal insufficiency in patients with
various underlying renal diseases, and found that this agent
delayed progressive deterioration of renal function [105]. This
protection was associated with a substantial decrease in blood
pressure and proteinuria. Therefore, I have no reason to believe
that different ACE inhibitors have dissimilar effects on the kidney.
DR. HARRTNGTON: What accounts for the increased risk of renal
failure in the U.S. black population compared to the white
population despite equivalent levels of hypertension? Dr. Madias
mentioned oligonephronia. What other factors might play a role?
DR. MouNToIiuus: Genetic factors, I presume. For example,
as I already mentioned, the sodium-hydrogen exchanger seems to
be genetically controlled, and the incidence of salt sensitivity has
long been known to be high among black Americans. On the other
hand, the expression of genes encoding several growth-promoting
peptides in renal tissue might be involved in the scarring process
of glomerulosclerosis [371.
DR. MADIAs: Recent data have shown that the DD polymor-
phism of the ACE gene is associated with progressive renal
disease, at least in the case of IgA nephropathy [106]. Is the ACE
polymorphism in patients with essential hypertension associated
with renal dysfunction?
DR. MOUNTOKALAKIS: To my knowledge, the only information
about a possible relationship between ACE gene polymorphism
and renal complications comes from a recent study in which ACE
genotypes were assessed by PCR both in hypertensive and nor-
motensive patients with non-diabetic renal disease who had been
entered in a randomized comparison of oral atenolol or enalapril
to prevent a progressive decline in renal function. The patients
with the DD genotype showed a significantly steeper decline of
glomerular filtration rate and were resistant to the renoprotective
action of enalapril [107]. The notion of a genetic contribution to
the progressive renal disease associated with hypertension is
particularly exciting. Large prospective studies including, in addi-
tion to ACE, other polymorphic markers, such as angiotensino-
gen, angiotensin receptors, cytokines, and lipoproteins, are defi-
nitely needed.
DR. C. STEFANIDIS (Pediatric Nephrologist, A. Kyriakou Chil-
dren's Hospital, Athens): A longitudinal study from Sweden re-
ported children with reflux nephropathy, even unilateral, who
developed hypertension and/or chronic renal failure later in life
[1081. What percentage of such patients are labeled as having
"idiopathic hypertension" in adulthood?
DR. MOUNTOKALAKIS: Reflux nephropathy has long been rec-
ognized as a cause of focal segmental glomerulosclerosis. How-
ever, hypertension occurs late in the course of this disease, when
proteinuria and decline of renal function are already established.
In any case, your comment further emphasizes the difficulty in
differentiating between cause and effect in hypertensive patients
with renal disease.
DR. D. TSAKIRIS (Hippokration General Hospita4 Thessaloniki):
John Reid in a 1993 article in Kidney International was skeptical
about the beneficial effect of antihypertensive treatment on hard
end-point events, particularly mortality [109]. He suggested that
we should not be very optimistic and expect to duplicate the
spectacular benefits of antihypertensive treatment that we saw in
the early 1960s, particularly in malignant hypertension. Do you
think that, in view of the newer and better nephroprotective
antihypertensive agents, we should expect a better future for our
patients?
DR. MouNroIcLATus: As I said at the conclusion of my presen-
tation, the main goal of antihypertensive treatment in patients
with mild to moderate hypertension—the large majority of the
hypertensive population—is to protect the brain and the heart's
vessels rather than the kidney. As far as the brain is concerned, we
have managed to dramatically reduce the risk of strokes attributed
to hypertension. The reduction in events related to coronary heart
disease was only about 50% of that expected, but this is not a
negligible gain. It has long been recognized that poor patient
compliance is a major factor contributing to inadequate blood
pressure control in the community. Although refinement of drug
treatment over the next years can be expected to enhance
compliance, for example, by permitting once-daily dosing and by
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limiting side effects, my personal view is that improved therapeu-
tic agents alone will not suffice; they must he combined with
comprehensive patient education.
Reprint requests to Dr. T D. Mountokalakis, Sotiria General Hospital, 152
Mesogion Avenue, 115 27 Athens, Greece
References
1. BRIGHT R: Cascs and obscrvations illustrative of renal disease
accompanied with secretion of albuminous urine. Guy's Hosp Rep
1:338—350, 1836
2. PAGE IH, MCCUBBIN JW: Renal Hypertension. Chicago, Year Book
Medical, 1968
3. GOLDBLATF PJ, GOHARA AF, KAHN NH, HAMPTON JA: Benign and
malignant nephrosclerosis and renovascular hypertension, in Renal
Patholo with Clinical and Functional Correlations, edited by Tisc-
HER CC, BRENNER BM, Philadelphia, Lippincott, 1989
4. PERERA G: Hypertensive vascular disease: description and natural
history. J Chronic Dis 1:33—42, 1955
5. VETERANS ADMINISTRATION COOPERATIVE STUDY GROUP ON ANTI-
HYPERTENSIVE AGENTS: Effects of treatment on morbidity in hyper-
tension. Results in patients with diastolic blood pressures averaging
115 through 129 mm Hg. JAMA 202:116—122, 1967
6. VETERANS ADMINISTRATION COOPERATIVE STUDY GROUP ON ANTI-
HYPERTENSIVE AGENTS: II. Effects of treatment on morbidity in
hypertension. Results in patients with diastolic blood pressures
averaging 90 through 114 mm Hg. JAMA 213:1143—1152, 1970
7. ZUCCHELLI P, ZUCCALA A: Primary hypertension— how does it cause
renal failure? Nephrol Dial Transplant 9:223—225, 1994
8. WIIELTON PK, KLAG MJ: Hypertension as a risk factor for renal
disease. Review of clinical and epidemiological evidence. Hyperten-
sion 13(suppl 1):119—127, 1989
9. UNITED STATES RENAL DATA SYSTEM: USRDS 1990 Annual Data
Report. The National Institutes of Health, National Institute of
Diabetes and Digestive and Kidney Disease. Bethesda, MD, 1990
10. EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION (EDTA) REG-
ISTRY: Annual Report on Management of Renal Failure in Europe.
XXIV, 1993
11. BRUNNER FP, SEIwooD NH: Profile of patients on RRT in Europe
and death rates due to major causes of death groups. Kidney mt
42(suppl 38):S4—S15, 1992
12. WHELTON PK, PERNEGER TV, BRANCATI FL, KLAG MJ: Epidemiol-
ogy and prevention of blood pressure-related renal disease. J Hyper-
tens l0(suppl 7):S77—584, 1992
13. RUILOPE LM, ALCAZAR JM, R0DIcI0 JL: Renal consequences of
arterial hypertension. J Hypertens 10(suppl 7):585—S90, 1992
14. SWALES J: Renal dysfunction in essential hypertension. Lancel 345:
740—741, 1995
15. BRAZY PC, STEAD WW, FITZWILLIAM iF: Progression of renal
insufficiency: Role of blood pressure. Kidney mt 35:670—674, 1989
16. BRAZY PC, FITZWILLIAM JF: Progressive renal disease: Role of race
and antihypertensive medications. Kidney mt 37:1113—1119, 1990
17. ROSTAND SG, BROWN G, KIRK KA, RUTSKY EA, DUSTAN HP: Renal
insufficiency in treated essential hypertension. N Engli Med 320:684—
688, 1989
18. WEI5sruc:II JM, DWORKIN LD: Does essential hypertension cause
end-stage renal disease? Kidney mt 41(suppl 36):S33—537, 1992
19. ROSANSKY SJ, HOOVER DR, KING L, GIBSON J: The association of
blood pressure levels and change in renal function in hypertensive
and nonhypertensive subjects. Arch intern Med 150:2073—2076, 1990
20. INNES A, JOHNSTON PA, MORGAN AG, DAVISON AM, BURDEN RP:
Clinical features of benign hypertensive nephrosclerosis at time of
renal biopsy. Q J Med 86:271—275, 1993
21. LINDEMAN RD, TOBIN JD, SHOCK NW: Association between blood
pressure and the rate of decline in renal function with age. Kidney mt
26:861—868, 1984
22. PERNEGER TV, NIETO J, WHELTON PC, KLAG Mi, COMSTOCK GW,
SzKL0 M: A prospective study of blood pressure and serum creati-
nine. JAMA 269:488—493, 1993
23. MADHAVAN 5, STOCKELL D, COHEN H, ALDERMAN MH: Renal
function during antihypertensive treatment. Lancet 345:749—751,
1995
24. SHUIMAN NB, FORD CE, HALL WD, BLAUFOX MC, SIMON D,
LANGFORD H, ET AL: On behalf of the Hypertension Detection and
Follow-up Program Cooperative Group: Prognostic value of serum
creatinine and the effect of treatment of hypertension on renal
function: results from the Hypertension Detection and Follow-up
Program. Hypertension 13(suppl 1):180—193, 1989
25. WALKER GW, NEATON JD, CUTLER JA, NEUWIRTH R, COHEN JD
Renal function change in hypertension members of the Multiple
Risk Factor Intervention Trial: racial and treatment effects. JAMA
268:3085—3091, 1992
26. DE LEEUW P, BIRKENHAGER WH: The renal circulation in essential
hypertension. J Hypertens 1:321—331, 1983
27. SHOBACK DM, WILLIAMS GH, MOORE TD, DLUHY RG, PODOLSKY 5,
HOLLENBERG NK: Defect in the sodium-modulated tissue respon-
siveness to angiotensin II in essential hypertension. J Clin Invest
72:2115—2124, 1983
28. VAN Hoovr IMS, GROBBEE DE, DERKX FHM, DE LEEUW P,
SCHALEKAMP MADH, HOFMAN A: Renal hemodynamics and the
renin-angiotensin-aldosterone system in normotensive subjects with
hypertensive and normotensive parents. N EngI J Med 324:1305—
1311, 1991
29. OFSTAD J, HORVEI G, KVAM Fl, MORKRID L, SEKSE 1, SVARSTAD E,
IVERSEN BM: Glomerular hemodynamics in progressive renal dis-
ease. Kidney mt 41(suppl 36):S8—S14, 1992
30. IVERSEN BM, SEKSE 1, OFSTAD J: Resetting of renal blood flow
autoregulation in spontaneous hypertensive rats. Am J Physiol 252:
F480—F486, 1987
31. MOORE LC, SCIINERMANN J, YARIMIZU 5: Feedback mediation of
SNGFR autoregulation in hydropenie and DOCA-salt loaded rats.
Am J Physiol 237(1):F63—F74, 1979
32. REMUZZI G, BERTANI T: Is glomeruloselerosis a consequence of
altered glomerular permeability to macromolecules? Kidney mt
38:384—394, 1990
33. BRENNER BM, MEYER TW, HOSTETITER TH: Dietary protein intake
and the progressive nature of kidney disease: The role of hemody-
namically mediated glomerular injury in the pathogenesis of progres-
sive glomerular sclerosis in aging, renal ablation, and intrinsic renal
disease. N Engl J Med 307:652—65 9, 1982
34. Luvr FC, HALLER H: Hypertension-induced renal injury: is mechan-
ically mediated interstitial inflammation involved? Nephrol Dial
Transplant 10:9—11, 1995
35. WHEELER DC: Lipids—what is the evidence for their role in pro-
gressive renal disease? Nephrol Dial Transplant 10:14—16, 1995
36. EL NAHAS AM: Renal scarring: the role of angiotensin II. Nephrol
Dial Transplant 10(suppl 9):28—32, 1995
37. EL NAHAS AM: Growth factors and glomerular sclerosis. Kidney (nt
41(suppl 36):S15—S20, 1992
38. PARVING HH, JENSEN HA, MOGENSEN CE, EVRIN PE: Increased
urinary albumin excretion rate in benign essential hypertension.
Lancet 1:1190—1194, 1974
39. CHRISTENSEN CK: Rapidly reversible albumin and /32-microglobulin
hyperexcretion in recent severe essential hypertension. J Hypertens
1:45—51, 1983
40. EDDY AA: Interstitial nephritis induced by protein-overload protein-
uria. Am J Pathol 135:719—733, 1989
41. MOYER JH, HEIDER C, PEVEY K, FORD RV: The effect of treatment
on vascular deterioration associated with hypertension, with partic-
ular emphasis on renal function. Am JMed 24:177—182, 1958
42. COOPE J, WARRENDER TS: Randomised treatment of hypertension in
elderly patients in primary care. Br Med J 293:1145—1151, 1986
43. DE LEEUW PW, on behalf of the European Working Party on High
Blood Pressure in the Elderly: Renal function in the elderly: results
from the European Working Party on High Blood Pressure in the
Elderly trial. Am J Med 90(suppl 3A):45S—49S, 1991
44. VAN BRUMMELEN P, WOERLEE M, SCHALEKAMP MADH: Long-term
versus short-term effect of hydrochlorothiazide on renal haemody-
namics in essential hypertension. Clin Sci 56:463—469, 1979
45. KRAUSS XH, SCHAI,EKAMP MADI-I, KOLSTERS G, ZAAI. GA, BIRKEN-
HAGER WH: Effects of chronic beta-adrenergic blockade on systemic
1652 Nephrology Forum: The renal consequences of arterial hypertension
and renal haemodynamic responses to hypertonic saline in hyperten-
sive patients. Clin Sd 43:385—391, 1972
46. RUILOPE LM, LAHERA V, Rooiclo JL, ROMERO JC: Are renal
hemodynamics a key factor in the development and maintenance of
arterial hypertension in humans? Hypertension 23:3—9, 1994
47. BAyER JH, JoNEs LB, GADDY P: Effects of prazosin therapy on blood
pressure, renal function, and body fluid composition. Arch Intern Med
144:1196—1200, 1984
48. HOLLENBERG NK, MEGGS LG, WIwAMs GH, KATZ J, GARNIC JD,
HARRINGTON DP: Sodium intake and renal responses to captopril in
normal man and in essential hypertension. Kidney mt 20:240—245,
1981
49. BRUNNER HR, NUSS8EROER J: Angiotensin converting enzyme inhi-
bition and the normal kidney. Kidney mt 31(suppl 20):S104—S107,
1987
50. KALRA PA, MAMT0RA H, HOLMES AM, WALDEK S: Renovascular
disease and renal complications of angiotensin-converting enzyme
inhibitor therapy. Q J Med 77:1013—1018, 1990
51. ANDERSEN S, RENNKE HG, BRENNER BM: The therapeutic advan-
tage of converting enzyme inhibitors in arresting progressive renal
disease associated with systemic hypertension in the rat. J Clin Invest
77:1993—2000, 1986
52. DWORKIN LD, FEINER HD, RANDAZZO J: Glomerular hypertension
and injury in desoxycorticosterone-salt rats on antihypertensive
therapy. Kidney mt 31:718—724, 1987
53. DWORKIN LD, GROSSER M, FEINER HD, ULLIAN M, PARKER M:
Renal vascular effects of antihypertensive therapy in uninephrecto-
mized SHR. Kidney mt 35:790—798, 1989
54. ZATZ R, ANDERSON S, MEYER TW,DUNN BR, RENNKEH, BRENNER
BM: Lowering of arterial pressure limits glomerular sclerosis in rats
with renal ablation and in experimental diabetes. Kidneymt 3l(suppl
20):5123—5129, 1987
55. PARVING HH, SMIDT UM, ANDERSEN AR, SVENDSEN PA: Early
aggressive antihypertensive treatment reduces rate of decline in
kidney function in diabetic nephropathy. Lancet 1:1175—1 178, 1983
56. ANDERSON R, RENNKE HG, GARCIA LD, BRENNER BM, RILEY SL,
SANDSTROM DJ: Short and long term effects of antihypertensive
therapy in the diabetic rat. Kidney mt 36:526—536, 1989
57. PERICO N, AMUCHASTEGUI SC, COLOSJO V, SONZOGNI G, BERTANI T,
REMUZZI G: Evidence that an angiotensin-converting enzyme inhib-
itor has a different effect on glomerular injury according to the
different phase of the disease at which the treatment is started. JAm
Soc Nephrol 5:1139—1 146, 1994
58. BJORCK S, NYBERG G, MULECH, GRANERUS 5, HERLITZ H, AURELL
M: Beneficial effects of angiotensin converting enzyme inhibition on
renal function in patients with diabetic nephropathy. Br Med J
293:467—470, 1986
59. MIMRANA, INSUA A, RIBSTEIN J, MONNIER L, BRINGER J, MIROUZE
J: Contrasting effects of captopril and nifedipine in normotensive
patients with incipient diabetic nephropathy. J Hypertens 6:919—923,
1988
60. VALENTINO VA, WILSON MD, WEART W, BAKRIS GL: A perspective
on converting enzyme inhibitors and calcium channel antagonists in
diabetic renal disease. Arch Intern Med 151:2367—2372, 1991
61. MATHIESEN ER, HOMMEL K, GIESE J, PARVING HH: Efficacy of
captopril in postponing nephropathy in normotensive insulin depen-
dent diabetic patients with microalbuminuria. Br Med J 303:81—87,
1991
62. LEWIS EJ, HUNSICKER IG, BAIN RP, ROHDL RD: The effect of
angiotensin-converting-cnzyme inhibition on diabetic nephropathy.
NEnglJMed 329:1456—1462, 1993
63. KASISKE BL, KALIL RSN, MA JZ, LIA M, KEANE WF: Effect of
antihypertensive therapy on the kidney in patients with diabetes: a
meta-regression analysis. Ann Intern Med 118:129—138, 1993
64. BAUER JH: Arc angiotensin-converting enzyme inhibitors the renal
protective antihypertensive drug of choice? Curr Opin Nephrol
Hypertens 4:427—431, 1995
65. LOUTZENIIISER R, EPSTEIN M: The renal hemodynamic effects of
calcium antagonists, in Calcium Antagonists and the Kidney, edited by
EPSTEIN M, LOUTZENIIISER R, Philadelphia, Hanley & Belfus, 1990,
pp 33—73
66. EPSTEIN M: Calcium antagonists and renal protection: current status
and future perspectives. Arch Intern Med 152:1573—1584, 1992
67. TER WIE PM, DE MICHELI AG, EPSTEIN M: Effects of calcium
antagonists on renal hemodynamics and progression of nondiabetic
chronic renal disease. Arch Intern Med 154:1185—1202, 1994
68. ANDERSON 5, RENNKE HG, BRENNER BM: Nifedipine versus fosino-
pril in uninephrectomized diabetic rats. Kidney mt 4 1:891—897, 1992
69. MIMRAN A, RIBSTEIN J: Angiotensin-converting enzyme inhibitors
versus calcium antagonists in the progression of renal diseases. Am J
Hypertens 7:73S—81S, 1994
70. BABA T, MURABAYASHI 5,TAKEBE K: Comparison of the renal effects
of angiotensin converting enzyme inhibitor and calcium antagonist in
hypertensive type 2 (non-insulin-dependent) diabetic patients with
microalbuminuria: a randomised controlled trial. Diabetologia 32:
40—44, 1989
71. BAKRIS GL, BARNHILL BW, SADLER R: Treatment of arterial hyper-
tension in diabetic humans: importance of therapeutic selection.
Kidney mt 41:912—919, 1992
72. SLAPATER R, VICKNAIR N, SADLER R, BAKRJS GL: Comparative
effects of different antihypertensive treatments on progression of
diabetic renal disease. Arch Intern Med 153:973—980, 1993
73. VIBERTI GC, HILL RD, JARRET RJ, ARGYROPOULOS A, MAHMUD U,
KEEN H: Microalbuminuria as a predictor of clinical nephropathy in
insulin-dependent diabetes mellitus. Lancet 1:1430—1432, 1982
74. MOGENSEN CE: Nephrology Forum: Microalbuminuria as a predic-
tor of clinical diabetic nephropathy. Kidney mt 31:673—689, 1987
75. BAUER JH, REAMSGP, HEWETI J, KLACHKOD, LAU A, MESSINA C,
KNAUSS V: A randomized, double-blind, placebo-controlled trial to
evaluate the effect of enalapril in patients with clinical diabetic
nephropathy. Am J Kidney Dis 20:443—457, 1992
76. ZUCCHELLI P, ZUCCALAA, BORGHI M, FUSAROLI M, SASDELLI M,
STALLONE C, SANNA G, GAGGI R: Long-term comparison between
captopril and nifedipine in the progression of renal insufficiency.
Kidney ml 42:452—458, 1992
77. GANSEVOORT RT, SLUITERWJ, HEMMELDER MH, DE ZEEUW D, DE
JONG PE: Antiproteinuriceffect of blood-pressure-lowering agents: a
meta-analysis of comparative trials. Nephrol Dial Transplant 10:1963—
1974, 1995
78. MAKI DD, MA JZ, LOUIS TA, KASISKE BL: Long-term effects of
antihypertensive agents on proteinuria and renal function. Arch
Intern Med 155:1073—1080, 1995
79. KLAHR 5: The kidney in hypertension—villain and victim. N Engl
J Med 320:731—733, 1989
80. JOINT NATIONAL COMMITrEE ON DETECTION, EVALUATION, AND
TREATMENT OF HIGH BLOOD PRESSURE: The fifth report of the Joint
National Committee on Detection, Evaluation, and Treatment of
High Blood Pressure (JNC V). Arch Intern Med 153:154—183, 1993
81. KLAHR S, LEVEY AS, BECK GJ, AGGIULA AW, HUNSICKER L,
KUSEK 1W, STRIKER G, FOR THE MODIFICATION OF DIET IN RENAL
DISEASE STUDY GROUP: The effects of dietary protein restriction and
blood-pressure control on the progression on chronic renal disease.
NEngIJ Med 330:877—884, 1994
82. PETERSON JC, ADLER 5, BURKHART JM, GREENE T, HEBERT LA,
HUNSICKER LG, KING AJ, KLAHR 5, MASSRY S, SEIFTER JL, FORTHE
MODIFICATION OF DIET IN RENAL DISEASE (MDRD) STUDY GROUP:
Blood pressure control, proteinuria, and the progression of renal
disease. Ann Intern Med 123:754—762, 1995
83. DUSSING R, SIFFERT W: Sodium-proton exchange and primary
hypertension. Hypertension 26:649—655, 1995
84. NOSADINI R, SEMPLICINI A, FI0RETFO P, LUSIANI L, TREVISAN R,
DONADON V, ZAN VVTE G, NIc0IOsI GL, DALI'AGLIo V, ZANUI-I-INI
D, VInERTI 0: Sodium-lithium countcrtransport and cardiorenal
abnormalities in essential hypertension. Hypertension 18:191—198,
1991
85. DAVIES JE, No LL, KOFOED-ENEVOLDSEN A, LI LK, EARLE KA,
TREvIsAN R, VIBERTI G: Intracellular pH and Na /H antiport
activity of cultured skin fibroblasts from diabetics. Kidney Int 42:
1184—1190, 1990
86. HURMAN WH, PRIORDE, YASSINEMD,WEDER AB: Nephropathy in
NIDDM is associated with cellular markers for hypertension. Diabe-
tes Care 16:815—818, 1993
87. BIGAzzI R, BIANCHI S, BALDARI D, SOFIERRI G, BALDARI G,
CAMPESE VM: Microalbuminuria in salt-sensitive patients. A marker
for renal and cardiovascular risk factors. Hypertension 23:195—199,
1994
Nephrology Fomm: The renal consequences of arterial hypertension 1653
88. FREEDMAN BI, IsKANDA.R SS, BUCKALEW VM, BURKART JM, APPEL
RG: Renal biopsy findings in presumed nephrosclerosis. Am J
Nephrol 14:90—94, 1994
89. Hsu H, CHURG J: The ultrastructure of mucoid "onion skin" intimal
lesions in malignant nephrosclerosis. Am J Pathol 99:67—80, 1980
90. GILBERT T, LELIEVRE-PEGORIER M, MERLET-BENICHOU C: Glomer-
ular damage in adult rats born with mild oligonephronia of protein-
deprived mothers (abstract). JAm Soc Nephrol 1:629, 1990
91. LAW CM, DE SWIET M, OSMOND C, FAYERS PM, BARKER DJP,
CRUDDAS AM, FALL CHD: Initiation of hypertension in utero and its
amplification throughout life. Br Med J 306:24—27, 1993
92. GENNSER G, RYMARK F, ISBERG PE: Low birth weight and risk of
high blood pressure in adulthood. Br Med J 296:1498—1500, 1988
93. LAw CM, BARKER DJP: Fetal influences on blood pressure. JHyper-
tens 12:1329—1332, 1994
94. LUCAS A, MORLEY R: Does early nutrition in infants born before
term programme later blood pressure? Br Med J 309:304—308, 1994
95. SHEP COOPERATIVE RESEARCH GROUP: Prevention of stroke by
antihypertensive drug treatment in older persons with isolated
systolic hypertension. JAMA 265:3255—3264, 1991
96. DAHLOF B, LINDHOLM LH, HANSSON L, SCHERTEN B, EKBOM T,
WESTER P-O: Morbidity and mortality in the Swedish Trial in Old
Patients with Hypertension (STOP-Hypertension). Lancet 338:1281—
1285, 1991
97. MRC WORKING PARTY: Medical Research Council trial on treat-
ment of hypertension in older adults. Br Med J 304:405—412, 1992
98. FOUQUE D, LAVILLE M, BOISSEL JB, CHIFFLET R, LABEEUW M, ZECH
PY: Controlled low-protein diets in chronic renal insufficiency:
meta-analysis. Br Med J 304:216—220, 1993
99. LOCATELLI F, MARCELLI D, COMELLI M, ALBERTI D, GRAzIANI G,
BUCCIANTI G, REDAEIIA B, GIANGRANDE A, THE NORTHERN ITALIAN
COOPERATIVE STUDY GROUP: Proteinuria and blood pressure as
causal components of progression to end-stage renal failure. Nephrol
Dial Transplant 11:461—467, 1996
100. MESSERLI FH, FROHLICH ED, DRE5LIN5KL GR, SUAREZ DH, ARIs-
TIMUNO GG: Serum uric acid in essential hypertension: an indicator
of renal vascular involvement. Ann Intern Med 93:817—821, 1980
101. BURT VI., WaLTON P, ROCELLA EJ, BROWN C, CUTLER JA, HIGGINS
M, Hoiw' MJ, LABARTHE D: Prevalence of hypertension in the US
adult population. Results from the third National Health and
Nutrition Examination Survey, 1988—1991. Hypertension 25:305—313,
1995
102. TRENKWALDER P, RULANO D, STENDER M, GEBHARD J, TRENK-
WALDER C, LYDTIN H, HENSE H-W: Prevalence, awareness, treat-
ment and control of hypertension in a population over the age of 65
years: results from the Starnberg Study on Epidemiology of Parkin-
sonism and Hypertension in the Elderly (STEPHY). J Hypertens
12:709—716, 1994
103. DIMMI1-r SB, EAMES SM, GOSLING P, WEST JNW, GIBSON JM,
LITTLER WA: Usefulness of ophthalmoscopy in mild-to-moderate
hypertension. Lancet 1:1103—1106, 1989
104. REAMS GP, BAUER JH: Effect of lisinopril monotherapy on renal
hemodynamics. Am J Kidney Dis 11:499—507, 1988
105. MASCHIO G, ALBERT! D, JANIN G, LOCATELLI F, MANN JFE,
MOTOLESE M, PONTICELLI C, RITZ E, ZUCCHELLI P, THE ANGIOTEN-
SIN-CONVERTING-ENZYME INHIBITION IN PROGRESSIVE RENAL INSUF-
FICIENCY STUDY GROUP: Effect of the angiotensin-enzyme inhibitor
benazepril on the progression of chronic renal insufficiency. N Engi
JMed 334:939—945, 1996
106. YOSHIDA H, MITARAI T, KAWAMURA T, KITAJIMA T, MIYAZAKI Y,
NAGASAWA R, KAWAGUCFII Y, KIJBO H, ICHIKAWA I, SAKAI 0: Role
of deletion polymorphism of the angiotensin converting enzyme gene
in the progression and therapeutic responsiveness of IgA nephrop-
athy. J Gun Invest 96:2162—2169, 1995
107. VAN ESSEN GG, RENSMA FL, DE ZEEUW 0, SLUITER WJ, SCHEFFER
H, APPERLOO AJ, DE JONG PE: Association between angiotensin-
converting-enzyme gene polymorphism and failure of renoprotective
therapy. Lancet 347:94—95, 1966
108. JACOBSON SH, EKLOF 0, LINS LE, WIKSTAD I, WINBERG J: Long-
term prognosis in post-infectious renal scarring in relation to radio-
logic findings in childhood: a 27-year follow-up. Pediatr Nephrol
6:19—24, 1992
109. REID JL: Drug treatment of hypertension. Kidney Int 44(suppl
42):S68—S70, 1993
